2006-04-04
Affibody signs distribution agreement with Abcam
STOCKHOLM, Sweden, April 4, 2006 - Affibody AB today announced an agreement in which Abcam will market Affibody® Research Reagents in its online catalog.
Affibody, a Swedish molecular imaging, targeted therapy and biotechnology company, today announced an agreement in which Abcam, a leading antibody supply company, will promote and distribute products from Affibody's portfolio of research reagents worldwide.
"We are delighted with this distribution agreement. Affibody's exciting new class of affinity ligands complement our range of top quality antibodies and further improves our ability to meet the high demand for research reagents worldwide," said Simon Renshaw, New Product Manager at Abcam.
Carl-Johan Dalsgaard, CEO of Affibody, added: "Abcam has an excellent reputation and market penetration and we appreciate that they operate as our distributor as it widens the important global sales channel for Affibody."